Table 1.
Demographic information and details about CI devices used by the subjects
| Participant | Specifier | Sex | Age (years) | Duration implanted (years) | Duration of deafness (years) | Etiology/acquired pre-/post-lingual | CI speech processor | CI electrode array | Pulse width (us) in proc. strategy | Electrodes deactivated |
|---|---|---|---|---|---|---|---|---|---|---|
| S1 | AB3 | M | 71 | 10 | 35 | Otosclerosis/post-ling. progression | HR90K | HiFocus 1J | 30.5 | EL12 |
| S2 | AB1 | M | 72 | 9 | 40 | Unknown/post-ling. | HR90K | HiFocus 1J | 26.0 | EL16 |
| S3 | AB6 | F | 69 | 5 | 64 | Unknown/peri-ling. | HR90K | HiFocus 1J | 35.0 | EL16 |
| S4 | AB24 | F | 48 | 2 | 3 | Unknown/post-ling. | HR90K Advantage | HiFocus MS | 34.1 | EL16 |
| S5 | AB26 | F | 56 | 4 | 20 | Unknown/post-ling. | HR90K Advantage | HiFocus MS | 23.3 | None |
| S6 | AB23 | F | 59 | 2 | 57 | Enlarged vestibular aqueduct/post-ling. | HR90K Advantage | HiFocus MS | 22.4 | None |
| S7 | AB25 | F | 64 | 2 | 33 | Sinus infection/post-ling. | HR90K Advantage | HiFocus MS | 18.0 | EL16 |
| S8 | AB2 | F | 57 | 10 | 26 | Possible otoxicity/post-ling. | HR90K | HiFocus 1J | 35.0 | EL16 |